Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Effects of Ublituximab on Motor Functions in Multiple Sclerosis — Stella

Home/Multiple Sclerosis (MS) - Relapsing-remitting/Effects of Ublituximab on Motor Functions in Multiple Sclerosis

View on ClinicalTrials.gov

Recruiting

Back to Multiple Sclerosis (MS) - Relapsing-remitting trials

Effects of Ublituximab on Motor Functions in Multiple Sclerosis

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(2 sites)

United States

Georgia State University, Atlanta, Georgia

Atlanta Neuroscience Institute, Atlanta, Georgia

Key details

Phase

Very early testing

Sponsor

Georgia State University

Collaborators

Atlanta Neuroscience Institute

Enrollment target

~25 participants

Started

November 2025

Primary completion

June 2026

Age range

18 Years – 55 Years

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.